Espindolol - PsiOxus Therapeutics

Drug Profile

Espindolol - PsiOxus Therapeutics

Alternative Names: MT-102; S-pindolol

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PsiOxus Therapeutics
  • Class Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Beta-adrenergic receptor agonists; Beta-adrenergic receptor antagonists; Serotonin 1A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cachexia
  • No development reported Muscular atrophy

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Muscle-wasting in United Kingdom (PO)
  • 20 Aug 2015 Phase II development for Cachexia is ongoing
  • 12 Nov 2013 Final efficacy data from a phase II trial in Cachexia released by PsiOxus Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top